List view / Grid view
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall…
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the…
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the risk of cancer recurrences or death by 42 percent in patients with BRCA-mutated high-risk early breast cancer.
The OlympiA trial will conduct its primary analysis early, after…
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
